Clinical Outcomes Associated with APOC3 Inhibition in Triglyceride Management

Novel therapies are addressing residual risk beyond LDL-cholesterol reduction for patients with moderate hypertriglyceridemia (150–499 mg/dL) and elevated cardiovascular risk. A recent Consultant360 Expert Q&A with Brian A. Bergmark, MD, an interventional cardiologist in the division of cardiovascular medicine at Brigham and Women's Hospital in Boston, MA, covered how the antisense oligonucleotide olezarsen, which targets apolipoprotein C-III, may influence triglycerides, apolipoprotein B–containing particles, and future cardiovascular outcomes. Use this quiz to test your understanding of the reported results and implications.

©2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Consultant360 or HMP Global, their employees, and affiliates.